SURVYR

TEM

Tempus AI, Inc.
$72.15
+$4.99 (7.43%)Oct 27 close
Healthcare CompareTechnicals
1M3M6M1Y2Y
-55%-38%-20%-3%+15%Oct 2025Oct 2026Apr 202652w high $92.0052w low $40.77
TEMSPY
Wall St. Highest PT $100.00 (+38.6%) Wall St. Avg PT $75.06 (+4.0%)
$42$57$72$88$103POC $50Hi $100Avg $75
Underwater Drawdown %Max DD -54.6%Current -21.2%
0.0%-54.6%
Relative Strength vs SPY-34.7% vs SPYUnderperforming
+72%0%-72%
1W
+$5.40 (8.09%)
1M
−$12.86 (15.13%)
3M
+$29.25 (68.18%)
6M
+$21.05 (41.19%)
YTD
+$13.10 (22.18%)
1Y
−$19.43 (21.22%)

Chart

Loading live chart…

Ratings & dials

1m · 5m · 15m · 1h · 4h · 1D

Analyst & Morningstar ratings

Consensus · Targets · Morningstar
Wall Street analyst consensus
SellHoldStrong Buy
Buy
20 analysts · mean score 2.20
1 = Strong Buy · 5 = Sell
Strong Buy210%
Buy840%
Hold945%
Underperform15%
Sell00%
Wall Street consensus
Analyst price targets
Current price$72.15
Average target$75.06
+$2.91 (+4.0%) upsideaverage target vs current price
CurrentAverageMedian
Low$35.00
Median$75.00
High$100.00
12-month Wall Street target range
Recent analyst rating changes · 30
Reiterated
2026-10-26 · HC Wainwright & Co. reiterated Buy on TEM
Reiterated
2026-10-26 · BTIG reiterated Buy on TEM
Reiterated
2026-10-23 · Needham reiterated Buy on TEM
Reiterated
2026-10-14 · JP Morgan reiterated Neutral on TEM
Reiterated
2026-10-12 · Canaccord Genuity reiterated Buy on TEM
Reiterated
2026-10-01 · Guggenheim reiterated Buy on TEM
All analyst rating changes ›

Third-party ratings, not SURVYR.'s views.

Key stats & company

Market value$13.1B
P/E (next 12 months, estimated)-1,555.3
52-week range$40.77 – $92.00
Revenue growth (latest quarter vs a year ago)+21.6%
Dividend yieldNo dividend
Analyst consensusBuy (18)
Average analyst price target$75.06 (+4%)

What they do

Tempus AI, Inc. operates as a healthcare technology company in the United States. It offers the Tempus platform, a closed-loop, full-stack, bi-directional integrations between a clinician's desktop and its laboratory diagnostic capabilities. The company also provides Lens, a software application for life sciences and advanced precision research.

Healthcare · Health Information Services
Valuation and fundamentals

Valuation & fundamentals

Loading the valuation from SEC filings…

For information only · Important disclosures

Grades vs sector

No sector grades for TEM yet. Grades rank S&P 1500 stocks within their sector and refresh after each daily data run, so a stock outside that index or newly covered has none.

Systematic Models

Not held by any of our 7 live models right now.

Quality Growth
Outside this model's universe or screens
 Momentum Top 15
Outside this model's universe or screens
 Momentum Blend
Not in the current book
 New Highs Growth
Outside this model's universe or screens
 SURVYR. Barbell Momentum & T-Bill Shield
Outside this model's universe or screens
 SURVYR. Physical AI Grid & Power
Outside this model's universe or screens
 SURVYR. Long Book
Not in the current book

Earnings & events

TEM earningsNext report in 6 days
Next report · quarter Sep 2026
Mon Nov 2, 2026Before the open
EPS consensus-$0.08 range -$0.17–$0.00
Revenue consensus$409.3M 20 analysts
Last 4 quarters · EPS vs estimate
Jul 30, 2026-$0.04est -$0.15+73.6%Above estimates
May 5, 2026-$0.13est -$0.20+35.4%Above estimates
Feb 24, 2026-$0.04est -$0.05+22.1%Above estimates
Nov 4, 2025-$0.11est -$0.18+37.3%Above estimates

In line = within 1% of the estimate.

Source: Yahoo Finance · report time: Nasdaq earnings calendar · refreshed 2026-10-27 18:23:46 ET
24-1125-0225-0525-0825-1126-0226-0526-07-0.310.00
EstimateActual (beat)Actual (miss)

Quarterly revenue

QuarterRevenueYoY
2026-06-30$382.5M+21.6%
2026-03-31$348.1M–
2025-12-31$367.2M–
2025-09-30$334.2M–
2025-06-30$314.6M–

News & catalysts

More news
What Happens To Tempus AI Stock If Its Cash Burn Continues?
Trefis · Oct 26
Should You Be Worried About Tempus AI Stock?
Trefis · Oct 20
Tempus AI Expands Strategic Collaborations to Drive Future Growth
Zacks · Oct 12
Rating changes
Reiterated
2026-10-26 · HC Wainwright & Co. reiterated Buy on TEM
Reiterated
2026-10-26 · BTIG reiterated Buy on TEM
Reiterated
2026-10-23 · Needham reiterated Buy on TEM
Reiterated
2026-10-14 · JP Morgan reiterated Neutral on TEM
Reiterated
2026-10-12 · Canaccord Genuity reiterated Buy on TEM
Reiterated
2026-10-01 · Guggenheim reiterated Buy on TEM

Third-party analyst actions, not SURVYR.'s views. All rating changes

Insider trades
Schoenherr Thomas Edward
CEO, Diagnostics · 2026-09-25
Sell
$873.9K
Lefkofsky Eric P
Director, CEO and Chairman, 10% owner · 2026-09-22
Sell
$12.6K
Lefkofsky Eric P
Director, CEO and Chairman, 10% owner · 2026-09-22
Sell
$1.1M
Lefkofsky Eric P
Director, CEO and Chairman, 10% owner · 2026-09-22
Sell
$2.3M
Lefkofsky Eric P
Director, CEO and Chairman, 10% owner · 2026-09-22
Sell
$492.4K
Lefkofsky Eric P
Director, CEO and Chairman, 10% owner · 2026-09-22
Sell
$1.9K
Lefkofsky Eric P
Director, CEO and Chairman, 10% owner · 2026-09-22
Sell
$163.6K
Lefkofsky Eric P
Director, CEO and Chairman, 10% owner · 2026-09-22
Sell
$341.6K
Lefkofsky Eric P
Director, CEO and Chairman, 10% owner · 2026-09-22
Sell
$73.9K
Lefkofsky Eric P
Director, CEO and Chairman, 10% owner · 2026-09-22
Sell
$34.1K
Lefkofsky Eric P
Director, CEO and Chairman, 10% owner · 2026-09-22
Sell
$3.0M
Lefkofsky Eric P
Director, CEO and Chairman, 10% owner · 2026-09-22
Sell
$6.1M

Stats refreshed 2026-10-27 18:23:46 ET from Yahoo Finance (yfinance). "–" means the data isn't available. Refresh now

Morning Brief (8 AM ET) & Market Close (4:30 PM ET), weekdays

Indexes, sectors, biggest movers, rates, top news, SURVYR. model changes and what's ahead. Free, two short emails each weekday.

Editions

Free. Not investment advice. Unsubscribe anytime.

SURVYR

Free to use. No card, no ads, no auto-renew.

Systematic research · Not investment advice · Hypothetical unless marked Live · Data: Yahoo Finance (15-min delayed), SEC EDGAR, House Clerk · Important disclosures · Contact desk@coteau.app

How it worksOur promiseTermsPrivacyData statusSend feedback
Coteau 0.9 · Oct 21, 2026